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Abstract
Background: Modified Vaccinia Ankara (MVA) is an attenuated strain of Vaccinia virus (VACV) currently employed in many
clinical trials against HIV/AIDS and other diseases. MVA still retains genes involved in host immune response evasion,
enabling its optimization by removing some of them. The aim of this study was to evaluate cellular immune responses (CIR)
induced by an IL-18 binding protein gene (C12L) deleted vector (MVADC12L).
Methodology/Principal Findings: BALB/c and C57BL/6 mice were immunized with different doses of MVADC12L or MVA
wild type (MVAwt), then CIR to VACV epitopes in immunogenic proteins were evaluated in spleen and draining lymph
nodes at acute and memory phases (7 and 40 days post-immunization respectively). Compared with parental MVAwt,
MVADC12L immunization induced a significant increase of two to three-fold in CD8
+ and CD4
+ T-cell responses to different
VACV epitopes, with increased percentage of anti-VACV cytotoxic CD8
+ T-cells (CD107a/b
+) during the acute phase of the
response. Importantly, the immunogenicity enhancement was also observed after MVADC12L inoculation with different
viral doses and by distinct routes (systemic and mucosal). Potentiation of MVA’s CIR was also observed during the memory
phase, in correlation with a higher protection against an intranasal challenge with VACV WR. Of note, we could also show a
significant increase in the CIR against HIV antigens such as Env, Gag, Pol and Nef from different subtypes expressed from
two recombinants of MVADC12L during heterologous DNA prime/MVA boost vaccination regimens.
Conclusions/Significance: This study demonstrates the relevance of IL-18 bp contribution in the immune response evasion
during MVA infection. Our findings clearly show that the deletion of the viral IL-18 bp gene is an effective approach to
increase MVA vaccine efficacy, as immunogenicity improvements were observed against vector antigens and more
importantly to HIV antigens.
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Introduction
Modified Vaccinia virus Ankara (MVA), an attenuated strain of
Vaccinia virus, was obtained following extensive serial passages on
primary chicken embryo fibroblasts (CEFs) [1]. During this
process of attenuation, MVA underwent deletion of 31 kbp
(15%) of its genome, as compared to its parental strain, including
a number of genes that contribute to viral evasion from host
immune responses and that determine virus host range [2,3]. As a
result, MVA lost its ability to replicate in most mammalian cells,
including primary human cells [4,5]. However, MVA has
conserved the characteristic ability to induce robust T-cell immune
responses against recombinant antigens, comparable to those
generated by more virulent replication competent VACV strains
[6,7,8]. Its safety as a vaccine vector has been largely proved
during the vaccination of more than 100.000 individuals against
smallpox without side effects [9]. Thus, the highly advantageous
safety characteristics showed by MVA, in addition to its ability to
express high levels and numbers of foreign genes, has converted it
as one of the leading candidates for evaluation as a vaccine vector
in multiple human clinical trials against different infection diseases
[10,11,12] and also melanoma [13].
Despite its large loss of genomic regions during the attenuation
process, MVA still retains viral genes involved in host immune
response evasion, raising the possibility to increase its vaccine
potential by removing some of them. Examples of this test of
concept have been recently shown in the literature, as the
enhancement of MVA immunogenicity after the removal of the
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secreted from infected cells [14]; or the increment of its vaccine
efficacy after the removal of the gene A41L that encodes for a
chemokine-binding protein [15]; or removal of the gene C6L that
encodes an inhibitor of IFN-b induction [16]. Another gene with
immunomodulatorypropertiesthathasbeenconservedintheMVA
genome is the 008L gene (C12L in VACV) that codes for an
interleukin 18 binding protein (IL-18 bp) [17,18]. IL-18 bps have
been described in humans and mouse as soluble inhibitors that bind
and neutralize endogenous IL-18 [19]. IL-18 has important roles in
the regulation of both innate and specific immune responses. This
cytokine is an important mediator in the Th1 response, primarily by
induction of IFN-c secretion from T-cells and natural killer (NK)
cells [20], it also enhances T and NK cell maturation, cytokine
production, and cytotoxicity [21,22,23]. Furthermore, IL-12 and
IL-18 act synergistically to promote Th1-mediated immune
responses, which play a critical role in defense against intracellular
microbes through the production of IFN-c [21].
Past reports have firstly described that the orthopoxviruses
VACV, ectromelia virus (EV), and cowpox virus express a soluble
IL-18 bp (vIL-18 bp), encoded by homologs of the variola virus
D7L ORF that is secreted from infected cells [17,24]. Expression
of this immunomodulator by distinct poxvirus strains emphasizes
the importance of IL-18 in the course of viral infections as immune
evasion mechanisms. The C12L gene of the VACV Western
Reserve (WR) strain was previously characterized in BALB/c
mice. Results showed that after inoculation of mice by intranasal
(i.n) route, a deletion mutant for this gene was attenuated and
induced lower weight loss and signs of illness compared to controls
[18]. Afterwards, the same authors performed a more in depth
study in which they demonstrated a role for the vIL-18 bp in
counteracting IL-18 in both the innate and the specific immune
response to VACV infection, highlighting the ability of IL-18 to
promote vigorous antiviral T-cell responses [25]. A more recent
study described the effects of the deletion of the IL-18 bp gene
from the genome of another replicating VACV strain, the Tiantan
Vaccinia virus (TV) vector, in which the deletion diminished the
virulence of the parental virus while immunogenicity was not
affected [26].
Although the studies in which the deletion of IL-18 bp coding
gene from the VACV WR genome documented an improvement
in the cellular immunity induced by the deletion mutant, in
relation to the MVA attenuated strain, the only report performed
until now in which the C12L gene was deleted from a MVA-BAC
suggested that no improvements in the cellular immunogenicity
could be made by the deletion of this gene [27].
In this study we have done an in depth characterization of the
immunological effects in mice after deleting the IL-18 bp coding
gene from the MVA genome. We found that IL-18 bp contributes
to immune response evasion during MVA infection, as the
deletion enhances T-cell immune responses against vector
antigens. Importantly, the deleted vector enhanced the immune
response to HIV antigens expressed from recombinant vectors.
Results
1. In vitro characterization of a MVA deleted of the
IL-18 bp gene: MVADC12L
To analyze the possible role of the C12L gene, codifying for IL-
18 bp, during MVA infection, we constructed an MVA with a
deletion in the C12L gene, following the methodology described
under Materials and Methods. To verify removal of the C12L viral
gene we performed a PCR with DNA extracted from CEFs
infected with parental or mutant virus (MVAwt or MVADC12L),
using oligonucleotide primers specific for MVA genomic sequenc-
es adjacent to the IL-18 bp gene locus. Figure 1A (left panel),
shows an amplified band of nearly 1100 bp from the wild type
template, whereas this band was absent in the PCR corresponding
to MVADC12L. As an internal control, we performed a PCR
amplification of another viral gene, the hemagglutinin gene (HA),
that produced a band of nearly 900 bp which was present in both
DNA templates. To directly verify the absence of C12L gene
expression, RT-PCR with RNA extracted from CEFs infected
with MVAwt or MVADC1L was performed. In the right panel of
Fig. 1A, a 363 bp fragment specific for the IL-18 bp RNA was
only present in the sample from CEFs infected with MVAwt.
Previous reports demonstrated that the C12L gene was not
essential for in vitro replication of VACV employing the WR strain
[18]. But, as differences in both viral genetic background and in
the generation process of the deleted mutant may affect the final
virus obtained, we therefore considered important to evaluate the
in vitro replication capacity of the generated MVADC12L mutant.
In agreement with the previous report, the virus yields for both
intracellular and extracellular virus measured in CEF cells were
indistinguishable between parental and mutant virus (Fig. 1B).
Previous studies have shown IL-18 binding activity for different
Vaccinia strains [17] including MVA, and that MVA expresses a
soluble factor that inhibits the IL-12-induced production of IFN-c
by mouse splenocytes [18], suggesting in an indirect form an IL-
18 bp activity. Thus, our following aim was to evaluate the loss of
function of IL-18 bp in the mutant virus demonstrating that MVA
C12L gene encodes a protein with a biological activity directly
correlated with IL-18. For this, a functional assay was conducted
using supernatants of CEFs infected cells to analyze the ability of
the C12L protein to inhibit the biological activity of mouse IL-18
(see Materials and Methods). In this assay mouse recombinant IL-
18 (rIL-18) was added to mouse splenocytes in the presence of
supernatants from MVA infected CEFs and 24 hs later the levels
of IFN-c secreted in the supernatants of the splenocyte cultures
were measured by ELISA. Figure 1C shows that preincubation of
rIL-18 with supernatants from CEF infected with parental MVA
triggered significant reduction of IL-18 biological activity,
indicated by reduction in the induction of IFN-c by mouse
splenocytes. The loss of function of this activity in MVADC12L
was demonstrated by the fact that if rIL-18 was incubated with
supernatants from CEFs infected with mutant MVADC12L, the
inhibition observed was abolished (Fig. 1C).
These findings revealed that we have successfully generated an
MVA deletion mutant of C12L, that the mutant maintained its
replicative capacity in cultured cells compared to the parental
virus and we proved that MVA encodes for a protein with a clear
biological activity that inhibits the action of IL-18 and this activity
is lost by deleting the viral gene.
2. MVADC12L shows an improved immunogenicity
associated with higher magnitude of IFN-c, IL-2 and
cytotoxic specific-CD8
+ T-cells
After the corroboration of the depletion of the IL-18 bp activity
from the MVA mutant generated, our next aim was to analyze the
modulation of IL-18 bp during the final adaptive immune
response generated against the viral vector antigens. To achieve
this aim, we firstly analyzed the modulation effects induced after
mice inoculation with a high dose of the virus (5610
7 pfu) by
intraperitoneal (i.p) route. The specific cellular immune response
was analyzed 7 days after inoculation, during the acute phase of
the response. Figure 2 describes the results found in BALB/c mice
(H-2
d). The specific anti-vector immunogenicity was evaluated
against the Vaccinia E3 and F2(G) CD8
+ T-cell epitopes
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expressed early during virus infection [28], similarly to the IL-18 bp
productwhich isexpressedbeforeviralDNAreplication.Therefore,
if the inhibition of the host IL-18 effect mediated by the viral IL-
18 bp is causing a depression of the final anti-viral cellular immune
response this would be expected to be reflected in the response
against these epitopes. Figure 2A (left panel) describes the specific
cellular immune response (IFN-c secreting cells) against the E3 and
F2(G) peptides found in the spleen of mice from both groups, where
it is shown that for those MVADC12L inoculated, significant
increments (p,0,01) (2 and 2,5 fold against E3 and F2(G) peptides
respectively) were found. Even more, a significant increment was
also observed when the IL-2 response was analyzed (Fig. 2A right
panel). Thus, after the results obtained by Elispot we did a more in
depth analysis by flow cytometry, restimulating the cells for 5 hours
with the specific stimulus. We corroborated the results found by
Figure 1. In vitro characterization of MVADC12L. (A) Corroboration of correct C12L gene deletion and abrogation of IL-18 bp expression. DNA
and total RNA were extracted from CEFs infected with MVADC12L, MVAwt or mock-infected cells (lanes 1, 2 and 3 respectively). C12L (left) and HA
(control gene, middle) sequences were amplified by PCR using specific primers. Absence of C12L mRNA (right) was assessed by RT-PCR using specific
primers. M: molecular weight marker (1 kb plus DNA ladder, Invitrogen). (B) Analysis of virus growth in CEFs after infection at low moi (0.01 pfu/cell),
with MVADC12L (white triangles) or MVAwt (black squares). Quantification of extra (upper panel) and intracellular (lower panel) virus yields at the
different indicated time points was performed as described in Materials and Methods. (C) Inhibition of mouse IL-18 biological activity. To evaluate the
inhibition of the IL-18-induced IFN-c production, mice naı ¨ve splenocytes were treated with Con A (200 ng/ml) and rIL-18 (5 ng/ml) in the presence of
supernatants (SN) from 10
5 CEFs that had been mock-infected or infected with the indicated viruses. The level of IFN-c in the culture SN was
determined by a standard ELISA assay 24 hs later. Statistically significant differences between MVAwt and MVADC12L: **p,0.01.
doi:10.1371/journal.pone.0032220.g001
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that the immunization with MVADC12L also generated an
increment in the cytotoxic activity (degranulation evaluated by
positive CD107a/b staining), which resulted significantly different
for the E3 peptide (p,0,05) (Fig. 2B, right panel).
Next, we analyzed the impact of the deletion of this gene (IL-
18 bp) in a different genetic background employing C57BL/6
mice (H-2
b), which were i.p inoculated with 5610
7 pfu/mouse of
MVAwt or MVADC12L. We selected three CD4 (E9L, H3L and
L4R) and one CD8 (B8R) previously defined T-cell epitopes. We
selected three CD4 (E9L, H3L and L4R) and one CD8 (B8R) T-
cell epitopes previously defined in this mouse model [28,29].
The Elispot analysis showed that in the case of the CD8
+
epitope, the MVADC12L generated an increment of 3 to 4-fold
(depending of the experiment) (Fig. 3A). It must be noted that the
improved immune response, afforded by the mutant MVA in this
mouse strain, was enhanced compared to the CD8
+ T-cell
responses studied in BALB/c. In relation to the CD4
+ T-cell
responses after MVAwt inoculation, the highest magnitude was
detected against the E9L peptide (expressed early during viral
replication) whereas minor responses were detected against the
other two epitopes which were expressed at later times. Increments
afforded by the MVA mutant against the CD4
+ peptides (Fig. 3A)
were of nearly two-fold in the IFN-c secreting cells determined by
Elispot after a restimulation period of 24 h, whereas extending this
period to 72 h and quantifying levels of specific IFN-c secreted,
the differences between both vectors were pronounced (Fig. 3B).
Thus, increments of 2.5 (H3L) to 3 fold (L4R) in relation to
MVAwt induced responses were observed. Moreover, in this
model we also evaluated if MVADC12L modulated the cytotox-
icity of the CD8
+ specific response, with the findings of a
significant increase in B8R specific CD107a/b cells in those mice
inoculated with the mutant MVA (Fig. 3C).
3. MVADC12L elicits higher cellular responses at lower
doses of immunization and by different immunization
routes
The results of the experiments described above clearly showed
that the deletion of the IL-18 bp codifying gene, produced
beneficial effects on the immunogenicity generated by MVA.
Those experiments were performed by inoculating mice with
5610
7 pfu, a somehow high viral dose, compared with the
standard doses (10
7 pfu) employed in the majority of the MVA
studies performed in mice and by i.p route. Thus, our following
aim was to analyze if at lower doses of immunization and after
application of the vector by other routes, the deletion of the IL-
18 bp still had an improved effect on the MVA vaccine potential.
In these experiments a five-fold lower viral dose was applied to
BALB/c mice (10
7 pfu/mouse) by alternative routes, such as the
intramuscular (i.m) and the intranasal (i.n) and, for comparison,
we also evaluated the responses generated after this lower viral
dose by the i.p route. In the left panel of Figure 4 the specific
response (number of IFN-c secreting cells) detected against both
CD8
+ peptides (E3 and F2(G)) were significantly incremented in
the MVADC12L i.p inoculated mice. Of note, the magnitude
found was comparable to that recorded after the 5610
7 pfu dose
(see Fig. 2A) specially for the E3 peptide (immunodominant),
whereas for F2(G) (less immunogenic in this model) lower
responses were detected. Notably, the i.m route resulted the most
effective in relation to the magnitudes generated, strengthening the
response in comparison to the i.p route (1200 vs 450 SFU/10
6 for
MVADC12L and 500 vs 250 SFU/10
6 for the MVAwt).
Importantly, we could also find an improvement in the response
with the mutated virus after the i.n immunization (Fig. 4 right
panel), a route with high relevance to the induction of mucosal
immune responses after MVA immunizations [30,31,32].
Thus, the findings shown in Figure 4 demonstrated that the
enhancements in the cellular immune responses generated by
MVADC12L were also exerted after the inoculation of lower viral
doses and by different immunization routes.
4. Analysis of the immune response generated by
MVADC12L in local draining lymph nodes to the site of
immunization
The primary adaptive immune response to most pathogens and
vaccines is initiated in regional lymph nodes draining peripheral
sites of antigen exposure. Lymph nodes are highly organized
structures designed to efficiently transfer antigen transported from
Figure 2. Immunogenicity of MVADC12L in BALB/c mice. Groups of four BALB/c mice were i.p immunized with 5610
7 pfu of MVAwt (white
bars) or MVADC12L (black bars), and seven dpi specific-CD8
+ T-cell responses against the E3 and F2(G) VACV peptides were evaluated in the spleen.
(A) The magnitude of the specific responses was measured by IFN-c (left) and IL-2 (right) Elispot assays. Background (RPMI negative control)
subtracted results are depicted as mean spot forming units (SFU) per 10
6 splenocytes 6 SD. (B) Quality of the response analyzed by ICS.
Degranulation of specific-CD8
+ T-cells was assessed with CD107a/b mAb (cytotoxicity marker) simultaneously with IFN-c production, after 5 hr of
stimulation with VACV peptides Results are expressed as mean % CD8
+ T-cells 6 SD. Statistically significant differences: *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0032220.g002
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processing and presenting antigen to lymphocytes. It is uncertain
how antiviral lymphocytes are activated in draining lymph nodes,
the site where adaptive immune responses are initiated. Recent
studies have demonstrated that naı ¨ve CD8
+ T-cells rapidly
migrated to VACV-infected cells in the peripheral interfollicular
region and then formed tight interactions with dendritic cells
(DCs), leading to complete T-cell activation [33]. It was also
shown how the administration route can target different APCs that
differentially shape the virus-specific cell-mediated immune
response of both CD4
+ and CD8
+ cells, in such a way that the
accessibility of MVA antigens to different APCs at the site of
immunization dictates the occurrence and extent of cellular
immunity [34]. Thus, considering the importance that the
draining lymph nodes (LNs) to the site of inoculation have in
the final outcome of the immune response, our following goal was
to analyze MVA-specific T-cell responses in the regional draining
LNs after different immunization routes. Responses were evalu-
ated in the inguinal LNs, (ILNs) after sub-cutaneous (s.c), and i.m
inoculations and cervical LNs (CLNs) after i.n immunizations. For
the three routes evaluated, we continued to observe differences
between both MVAs, finding improved T-cell responses in those
groups MVADC12L immunized. Importantly, we found that after
s.c inoculation in BALB/c differences between both MVAs were
incremented in the ILNs, resulting in a three-fold superior
improvement of the responses against E3 and F2(G) peptides
(Fig. 5A). Therefore, in line with previous reports we found that
the final T-cell response was influenced by the APCs at the site of
immunization, as differences between both vectors detected in the
spleen, after administration by the i.p route with the same or even
higher viral doses (1 to 5610
7 pfu/mouse), were always nearly 2-
fold. After i.n immunization, increments in the responses found in
the CLNs of MVADC12L were nearly 2-fold (Fig. 5B), following a
similar pattern to that previously detected in the spleen for this
mouse strain. In C57BL/6 mice we could also find in the draining
ILNs an incremented response against both peptides analyzed
(B8R and E9L) when MVADC12L was applied (Fig. 5C).
The findings shown in Figure 5 revealed that the CIR
enhancements generated by MVADC12L in infected mice were
also detected in the draining lymph nodes to the site of inoculation
of the viral vector.
5. MVADC12L improves T-cell memory responses
conferring a higher grade of protection than parental
MVA after challenge with virulent VACV (WR)
Memory CD8
+ T-cells are an important component of acquired
immunity to viruses and other pathogens and represent the main
final aim of T-cell vaccines. Their principal characteristic is the
capacity to persist for extended periods, responding more rapidly
and more vigorously than naı ¨ve T-cells when they reencounter the
same antigen [35,36]. Thus, we proceeded to define if after
contraction of the specific immune response triggered by both
vectors, differences in memory responses induced by MVADC12L
versus MVA still persist with time.
Figure 6 (A–B) shows the specific immune responses detected 40
days after immunization with a dose of 10
7 pfu/mouse. It must
be noted that, for these experiments, the Elispot assays were
Figure 3. Immunogenicity of MVADC12L in C57BL/6 mice.
Groups of four C57BL/6 mice were i.p vaccinated with 5610
7 pfu of
MVAwt (white bars) or MVADC12L (black bars) and seven dpi T-cell
responses against VACV peptides B8R (CD8
+-specific), E9L, H3L and L4R
(CD4
+-specific) were evaluated in the spleen. (A) The magnitude of the
response was measured by IFN-c Elispot assay after 24 hr stimulation.
Background (RPMI negative control) subtracted results are depicted as
mean IFN-c spot forming units (SFU) per 10
6 splenocytes 6 SD. (B) IFN-
c production in splenocyte-culture supernatants was evaluated by
ELISA after 72 hr stimulation. (C) Quality of the response was analyzed
by ICS. Degranulation of specific-CD8
+ T-cells was assessed with
CD107a/b mAb together with IFN-c production, after 5 hr stimulation
with the indicated peptides. Results are expressed as mean % of specific
CD8
+ T-cells 6 SD. Statistically significant differences: *p,0.05,
**p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0032220.g003
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(detecting responses with a sensitivity two to three fold higher), in
order to detect with a high precision the memory responses that
are of lower magnitude with respect to those of the acute phase.
Importantly, after 40 days, improvements in the immunogenicity
induced by MVADC12L were still detected in both mouse strains.
Significant differences in immune responses induced by both
vectors were found for VACV-CD8
+ peptides in BALB/c and
C57BL/6 mice, and in this last strain differences against the E9L
CD4
+ peptide were also detected. In the C57BL/6 mice we also
analyzed immunity detected in the ILNs, finding a similar trend in
the responses generated by both MVA vectors. As observed in
Fig. 6 A–B, during the memory phase, MVADC12L produced
T-cell responses nearly two-fold superior (increments varied from
1,4 to 3 fold) than those induced after MVAwt inoculation.
Then, our next aim was to evaluate if the deletion of IL-18 bp
could improve the MVA vaccine potential, monitoring whether
the different levels of memory T-cell responses were correlated
with an enhanced protection against a virulent strain of VACV.
For this, three groups of 10–11 BALB/c mice per group were
firstly i.p immunized with 10
6 pfu/mouse of MVADC12L,
MVAwt or mock-treated, and 45 days later they were challenged
by i.n inoculation with 2610
6 pfu of Vaccinia virus WR (this is
about 20-fold the LD50). In these experiments, a low dose of MVA
immunization was used to reduce the levels of neutralizing
antibodies to the virus, in order to perform a more direct
Figure 4. MVADC12L elicits higher cellular responses at lower doses of immunization and by different immunization routes. Groups
of four BALB/c mice were immunized by intraperitoneal (IP) intramuscular (IM) or intranasal (IN) route with 10
7 pfu of MVAwt (white bars) or
MVADC12L (black bars) and seven dpi specific-CD8
+ T-cell responses against E3 and F2(G) peptides were evaluated in the spleen. The magnitude of
the response was measured by IFN-c Elispot assay after 24 hr stimulation. Background (RPMI control) subtracted results are depicted as mean IFN-c
spot forming units (SFU) per 10
6 splenocytes 6 SD. Statistically significant differences: *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0032220.g004
Figure 5. Analysis of the immune response generated in local draining lymph nodes (LNs) to the site of immunization. Groups of four
mice were immunized as indicated in the bar charts with 10
7 pfu of MVAwt (white bars) or MVADC12L (black bars) and seven dpi specific T-cell
responses against the indicated peptides were evaluated in the regional draining LNs to the different immunization routes as depicted in the Figure.
The magnitude of the response was measured by IFN-c Elispot assay after 24 hr stimulation. Background (RPMI control) subtracted data are depicted
as mean IFN-c spot forming units (SFU) per 10
6 cells 6 SD. SC: subcutaneous; IN: intranasal; IM: intramuscular; ILN: inguinal lymph nodes; CLN: cervical
lymph nodes. Statistically significant differences: *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0032220.g005
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protection afforded.
In mock-vaccinated control mice VACV infection resulted in the
onset of respiratory disease, high grade of weight loss, detecting .30%
of accumulative weight loss at day nine 9 post-infection (p.i) (Fig. 6C).
As it must be expected, mice previously immunized with MVA vectors
showed a clear reduction in their illness signs, compared to mock-
vaccinated ones. Significant differences in illness signs between MVA
inoculated groups and mock animals were detected from day 6 to day
8 and at day 9 mock mice had to be sacrificed (Fig. S1).
Figure 6. MVADC12L improves T-cell memory responses conferring a higher grade of protection against a VACV challenge. (A)
Groups of four BALB/c mice were i.p immunized with 10
7 pfu of MVAwt or MVADC12L. At 40 dpi the magnitude of the T-cell response in the spleen
was measured by a more sensitive IFN-c Elispot assay as described in Materials and Methods. (B) Groups of four C57BL/6 mice were i.m inoculated
with 10
7 pfu of the indicated vectors and at 40 dpi the magnitude of the response was evaluated by IFN-c Elispot assay against the CD8
+ (B8R) and
CD4
+ (E9L) VACV peptides in the spleen and ILNs. (C) Groups of 11 BALB/c mice were i.p vaccinated with 10
6 pfu of MVAwt, MVADC12L or mock
immunized and 45 dpi all animals were intranasally challenged with 2610
6 pfu of the VACV WR strain. Mice were daily weighed during 12 days and
the mean % of accumulative weight loss for each group was calculated (see Materials and Methods). (D) Detailed % of accumulative weight loss of
individual animals within each indicated group at 5, 6, 7 and 8 days post-challenge, median values are shown. (E) Groups of 4 BALB/c mice were i.p
immunized with 2610
6 pfu of the vectors and 40 dpi the response against E3 peptide and/or P815-MVA infected cells was evaluated by IFN-c and IL-
2 Elispot assays. Background (RPMI control) subtracted results are depicted as mean spot forming units (SFU) per 10
6 cells 6 SD. Statistically
significant differences: *p,0.05, ***p,0.001.
doi:10.1371/journal.pone.0032220.g006
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fifth day (13%) and then began to recover rapidly; while in the
MVAwt group the loss of weight continued until the sixth day
inclusive (17%) (Fig.6C). It must also be noted, that in these mice
the recovery was more slowly from day 5 to day 8 p.i, with
significant differences between both groups at days 7 and 8 p.i
(Fig. 6D). Moreover, significant differences in illness signs between
both groups were also found at days 7 and 8 p.i (Fig. S1). To
provide evidence that prior to the time of challenge the
MVADC12L infected mice generated an enhanced cellular
immunity over the MVA group, splenocytes from BALB/c mice
i.p inoculated with 2610
6 pfu of the viruses, were isolated and
tested for cellular responses against VACV antigens (P815 cells
infected with MVA and E3 peptide). Importantly, significant
higher numbers of both IFN-c and IL-2 secreting cells were
detected in the MVADC12L group (Fig. 6E).
These data showed that the improvements in the cellular
immune responses generated after MVADC12L immunization
were maintained for longer times, during the memory phase, and
moreover this enhancement in the immune response was reflected
in a major protective capacity against an intranasal WR challenge.
6. Quality of the specific anti-VACV response induced in
the absence of IL-18 bp viral activity
Then, our following aim was to do a more in depth analysis to
characterize the quality of the cellular immune responses
generated by the MVADC12L mutant. Based on the results
described in the previous sections, the i.m immunization route was
selected and the viral dose employed was 10
7 pfu/mouse.
Figure 7A depicts the results from Elispot assays evaluating the
number of B8R specific T-cells that secrete IFN-c or IL-2,
demonstrating significant increments in both CD8
+T-cell types in
those C57BL/6 mice immunized with MVADC12L. Figure 7B
shows data of ICS analysis of the different functions exerted by
specific B8R CD8
+ T-cells found in the spleen of MVAwt or
MVADC12L immunized mice. When total IFN-c, TNF-a,o r
CD107a/b positive cells against the B8R peptide were analyzed
(Fig. 7B left panel) it can be seen that MVADC12L generated an
increment in the proportion of cells positive for any of the
functions. These results were in concordance with data shown in
Figure 3C; although in that experiment the i.p route was used and
the viral dose was five times higher. The polyfunctionality pattern
of the T-cell response indicated that the MVADC12L immuniza-
tion did not change in relation to that generated after MVAwt
immunization, as similar percentages of cells positive for the three,
two or one of the functions studied were found in both groups of
mice (Fig. 7B right panel).
We also analyzed the capacity of the specific T-cells to secrete
IFN-c and TNF-a in both acute (7 days p.i) and memory phases
(40 days p.i) of the response (Fig. 7C). Data showed that at both
the peak of the T-cell response and also at late times, when the
contraction of the response had already occurred, CD8
+ T-cells
(anti-B8R) from MVADC12L inoculated mice produced higher
levels of IFN-c and TNF-a than MVA mice. In relation to the
CD4 peptides (E9L and L4R), increased levels of both cytokines
were found for the mutant MVADC12L restimulated splenocytes
during the acute phase, whereas at the memory phase as the
intensity of the CD4
+ T-cell response was diminished we could
only detect differences in IFN-c levels. Finally, we decided to
analyze the T-cell functional avidity as another important T-cell
function directly correlated with its quality. This T-cell capa-
city is a reflection of the efficiency of the effector cells, as it
measures the ability of the cells to recognize its specific antigen at
low concentrations. Thus, to investigate if the MVADC12L
immunization could have altered the avidity of the T-cell response,
we evaluated the functional avidity of CD8
+ E3-specific T-cells
after i.m immunization of BALB/c mice with 10
7 pfu of each
MVA vector. For this, Elispot assays at different peptide
concentrations were performed. Fig. 7D shows that the curves
obtained with splenocytes from both mice groups (MVAwt or
MVADC12L immunized) were similar, showing no differences
among the functional activities. Thus, values for 50% of the
maximal T-cell responses (EC50) did not differ significantly among
groups: EC50 values calculated with a sigmoid dose-response curve
(GraphPad software) were 0,014 (MVAwt) and 0,008 mg/ml
(MVADC12L).
These findings corroborated the results shown in previous
sections demonstrating that after MVADC12L immunization a
higher proportion of anti-viral specific T-cells secreting IFN-c,
TNF-a, IL-2 or with cytotoxic capacity were generated. Moreover,
we demonstrated that this enhancement was not at the expense of
the quality of the response, analyzed by polyfunctional or avidity
properties.
7. MVADC12L induced higher cellular responses against
recombinant HIV antigens compared to MVA in DNA
prime/MVA boost immunizations
The renewed interest for the development of poxvirus-based
HIV vaccines has been boosted by the recent results obtained from
the phase III RV-144 trial in Thailand [37]. While these studies
showed modest efficacy (31%), they provide for the first time
evidence of a candidate HIV vaccine capable of preventing HIV
infection. Since a poxvirus vector (canarypox) was used in the RV-
144 trial and the T-cell immune response was poor, it suggested
that a poxvirus vector with more potent capacity to induce T-cell
responses to HIV antigens might be more effective. Thus, the last
aim of this work was to analyze if the enhancement observed
against VACV antigens after deletion of IL-18 bp gene could also
be induced against different HIV recombinant genes expressed
from MVADC12L vectors.
For these experiments, immunizations based on DNA prime/
MVA boost schemes were applied, but now employing recombi-
nant MVA vectors expressing NefBF [38] or a recombinant MVA
expressing codon-optimized Env as a monomeric gp120 and a
polyprotein Gag-Pol-Nef from clade C (referred as MVA-C) [39].
The immunization schemes are described in Figure 8A. Fig. 8B–C
shows the HIV specific responses detected 7–10 days after the last
immunization. When the NefBF antigen was used, it can be clearly
seen that if the booster dose was MVADC12L-NefBF, the
reactivity against NefBF peptides (overlapping peptides represent-
ing the entire protein) was significantly improved (Fig. 8B), and
even more, a higher -albeit not significant- level of cross-reactivity
against B peptides was also found in mice that received the DNA-
NefBF/MVADC12L-NefBF scheme.
When the recombinant MVA-C vectors were administered at
booster, IL-18 bp modulation on the immunity against a wider
range of HIV antigens could be observed. As shown in Fig. 8C the
magnitude of the T-cell responses, measured against the total pool
of peptides represented in the HIV antigens, was higher in
splenocytes from mice boosted with MVADC12L than boosted
with MVA. The right panel depicts the responses against the
different HIV peptide-pools contained within the four different
HIV proteins. Remarkably, the enhancement produced by
MVADC12L-C was observed for most of the peptide-pools
evaluated. Of note, significant higher responses against five out
of eight pools were found in the MVADC12L-C group (Fig. 8C).
These findings (Figure 8) show that optimization of the immune
response generated after MVADC12L can also be achieved
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responses with higher magnitude and amplitude after a DNA
prime/MVA boost scheme. These data are of significance in the
design of future poxvirus-based HIV vaccines.
Discussion
There is a substantial need to improve the immunogenicity of
MVA-based vaccines, which are currently being developed for use
against a number of prominent infectious diseases including AIDS,
malaria, and tuberculosis, as well as human cancers [40].
The proof of concept that MVA vaccine potential can be
improved after removing viral genes involved in host immune
response evasion was demonstrated in previous studies in which
genes as the one encoding interleukin 1b (IL-1b)-binding protein,
or the A41L and C6L genes which blocks the action of CC-
chemokines and IFN-b were removed [14,15,41]. In the present
study we demonstrate for the first time that a MVA deleted of the
gene coding for the IL-18 bp (C12L) showed an enhanced T-cell
immunogenicity against both CD8
+ and CD4
+ T-cell VACV
peptides, and more importantly this optimization was also exerted
against HIV recombinant antigens.
It was previously demonstrated that IL-18 bp was produced in
response to VACV (WR strain) infection in vitro [17,18]. The
relevance of the C12L gene during infection of mice with this viral
strain, was shown by an augmentation of NK cytotoxicity and
CTL responses after infection with a C12L VACV deletion mutant
[25]. And more recently, it has been demonstrated that deletion of
Figure 7. Quality characterization of the specific T-cell anti-VACV immune response. (A) Groups of four C57BL/6 mice were i.m immunized
with 10
7 pfu of MVAwt (white bars) or MVADC12L (black bars), and seven dpi the magnitude of the T-cell response against B8R peptide in the spleen
was measured by IFN-c and IL-2 Elispot assays and (B) degranulation of specific-CD8
+ T-cells was assessed with CD107a/b staining simultaneously
with IFN-c and TNF-a production by ICS, after 5 hr of stimulation with B8R peptide. Analysis of the total B8R specific-CD8
+ T-cells expressing each of
the functions (left panel) and polyfunctionality of the specific-CD8
+ T-cells were performed (right panel). Bars represent the frequency of CD8
+ T-cells
expressing the particular combination of functions indicated on the x axis. Results are expressed as mean % CD8
+ anti-B8R T-cells 6 SD. Each pie
chart represents the mean contribution of each effector function to the total response. Green sectors stand for CD8
+ cells positive for only one
function (SP), yellow sectors stand for bifunctional CD8
+ cells (DP), and red sectors stand for trifunctional cells (TP). (C) Groups of four C57BL/6 mice
were i.m immunized with 10
7 pfu of MVAwt or MVADC12L and 7 (acute) or 35 (memory) dpi, specific cytokine production in splenocyte-culture
supernatants was evaluated by ELISA after 72 hr stimulation with the indicated peptides. (D) Splenocytes from BALB/c mice i.m immunized with
10
7 pfu of MVAwt (green) or MVADC12L (red) were assayed by IFN-c Elispot against serial dilutions of VACV E3 peptide. T-cell functional avidity is
defined as the concentration required to achieve half-maximal of the response (EC50). Data represents the percentage of the maximal response (net
number of SFU per 10
6 cells stimulated with a peptide concentration of 20 mg/ml). Statistically significant differences: *p,0.05, **p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0032220.g007
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strain in both mice and rabbit models [26]. It was previously
reported that the MVA genome encoded an IL-18-binding activity
[17]. However, here we described for the first time that MVA
encodes for a protein with a clear biological activity that inhibits
the action of IL-18, and that deletion of the C12L viral gene (008L
in MVA) abolished this inhibitory activity. Then, the first
experiments performed in BALB/c mice (Fig. 2) indicated the
importance of IL-18 modulation on MVA immunogenicity. Thus,
mice infected with MVADC12L, and therefore in the absence of
an inhibitory effect against host IL-18, generated responses against
CD8
+ epitopes of a higher magnitude, rendering two-fold
increments in the number of specific IFN-c and IL-2 secreting
cells against the E3 and F2(G) VACV peptides.
In C57BL/6 mice, these observations were corroborated, finding
significant T-cell enhancements that reached three to four-fold
increments against the immunodominant CD8
+ B8R peptide, and
alsoapositivemodulationagainst CD4
+epitopes.Acriticalfunction
of the CD8
+ T-cells is their cytotoxic capacity, a parameter which
directly correlates with protective anti-viral immunity. Importantly,
we found that in both mouse strains BALB/c and C57BL/6,
MVADC12L administration also improved the number of CD8
+
T-cells with cytotoxic properties (cells positive for the CD107a/b
markers). The only previous data indicating a direct evidence of an
augmentation of the CTL activity after deletion of the C12L gene,
was documented for the WR strain [25].
In a relative recent publication in which the C12L gene was
deleted from the MVA genome employing the methodology of
recombination-mediated genetic engineering of a bacterial
artificial chromosome (BAC), the authors did not find an
improvement in the CD8
+ T-cell immunogenicity [27]. However,
in that study a single viral dose and administration route were
analyzed (10
6 pfu by intradermal (i.d) route), in contrast with the
different routes and varied viral doses that we have analyzed in the
present study. It must also be noted that, after the application of
the BAC technology, among the five VACV deleted genes already
described in previous works [14,15,18,42,43], only the deletion of
the B15R gene was associated with an improvement in the MVA
immunogenicity.
The efficacy of MVA immunization has been investigated in
several animal models and by different immunization routes
[32,40,44,45]. In relation with this, the relevance that the
application of distinct routes of immunization could have on the
final adaptive cellular response induced after MVA immunization
Figure 8. MVADC12L induced strengthened cellular responses against recombinant HIV antigens compared to MVA after DNA/
MVA immunizations. (A) Description of the different vectors employed in the DNA/MVA immunization schemes applied, each group consisted of
three to four BALB/c mice. (B) Seven days after the boost, specific-CD8
+ T-cell responses against NefBF (homologous) or NefB (heterologous) peptides
were evaluated in the spleen. (C) Ten days after the boost specific responses against HIV-1 subtype C antigens were evaluated in the spleen. To the
left it is depicted the responses found against the total pool of peptides analyzed, in the right panel it can be seen the detailed analysis showing the
pool of peptides targeted comprising the different HIV antigens that are expressed from the vectors. The magnitude of the response was measured
by IFN-c Elispot assay after 24 hr stimulation. Background (RPMI control) subtracted results are depicted as mean IFN-c spot forming units (SFU) per
10
6 splenocytes 6 SD. Statistically significant differences: *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0032220.g008
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administration after i.d. or i.m routes target different APCs that
differentially shape the virus-specific cell-mediated immune
response. In the present study, the improved immunogenicity
described for the MVADC12L mutant vector was corroborated
after the inoculation of different viral doses (from 5610
7 to 2610
6
pfu/mouse) and even more, this optimization was verified after i.p,
i.m or i.n immunizations. In relation to the impact that the
inoculation route could have on the final adaptive immune
response generated, comparing the i.p vs the i.m routes, we found
that after this last route a significant enhancement (of nearly 3
times) on the final magnitude of the specific responses detected in
the spleen were observed against both peptides and in animals
inoculated with MVA or MVADC12L. A possible explanation to
the results obtained here may be differences in the principal types
of APCs that are participating in the initiation of the immune
response after i.p or i.m inoculation. Another factor that may be
influencing the differences observed between the i.p and i.m
routes, may be a differential pattern of the MVA viral gene
expression. Therefore, previous studies have demonstrated higher
levels of gene expression post-intramuscular inoculation than those
recorded after i.p inoculation [46].
Given the application of MVA as a vaccine vector, the
observation that the beneficial immunogenicity effects after the
deletion of the C12L gene were also observed during the memory
phase is an issue of high relevance. Our results suggest the
importance of IL-18 to induce and longer maintain the
improvements induced in the anti-viral T-cell immune responses.
Early exposure to distinct cytokines most commonly influences the
balance between the development of short-lived, terminally
differentiated effector cells and memory precursors CD8
+ T-cells
[47]. Beyond the induction phase, cytokines contribute to the
regulation of the contraction of the response, as well as the long-
term maintenance of memory CD8
+ T-cells. It has been described
that increasing the amount or duration of IL-12 stimulation of
CD8
+ T-cells results in elevated expression of the transcription
factor T-bet (Tbx 21), which enforces an effector (CD127
loKLRG-
1
hi) phenotype [48]. On the other hand, signaling by cytokines
with a common cc cytokine receptor: IL-2, IL-7, and IL-15,
activate prosurvival signals and up-regulation of the anti-apoptotic
molecule, Bcl-2 [49]. Regarding the relevance of IL-18 in the
promotion of T-cell memory responses, a recent paper indicated
that a positive regulatory loop involving IFN-c and IL-18 signaling
contributes to the accelerated memory CD8
+ T-cell proliferation
during a recall response to antigens presented by DCs [50].
Although another study described that, despite the induction of
IL-18-related genes during the contraction phase, they do not play
major roles in regulating the dynamics or function of the T-cell
response to Listeria Monocytogenes or VACV infection [51].
The biological relevance of the immunization with the
MVADC12L mutant was also evaluated by analyzing its efficacy
in conferring protection against a challenge with the virulent
VACV WR strain in the well established i.n challenge BALB/c
model [52]. In these experiments, mice were inoculated with low
immunizing doses (2610
6 pfu, by i.p route), after which low levels
of anti-VACV antibodies were induced [7], in order to have a
window for a more direct correlation between T-cell immunity
induced and protection afforded. But, it must be taken it into
account that although low levels of anti-VACV antibodies are
induced after that viral dose, possibly higher levels may be present
in MVADC12L inoculated mice, as it was found in mice
inoculated with 10
7 pfu/mice (data not shown). The challenge
experiments showed that mice that received MVADC12L
presented an increased protection against the WR challenge at
the memory T-cell phase, highlighting the improved protective
capacity of the T-cell responses generated by the IL-18 bp deleted
vector. Previous studies performed with other genes deleted MVA
mutants also correlated the improvements on the cellular
immunity with an enhancement in their protective capacity
[14,15]. To notice, this is the first study in which the C12L gene
effects on the T-cell memory responses are analyzed, as in other
previous works in which the C12L gene was characterized,
immune responses were only studied during the early phase.
When we analyzed the vaccine potential of the MVADC12L
with respect to recombinant expressed antigens, in particular HIV
antigens, we applied the MVA dose as a booster in relation to the
recombinant antigens (in a DNA/MVA scheme). We employed
two MVADC12L recombinants one expressing a single HIV
protein: NefBF [38] and another one expressing a codon-
optimized Env as a monomeric gp120 and a syn polyprotein
Gag-Pol-Nef of HIV-1 from clade C [39]. Importantly, in both
cases the delivery of the HIV antigens during the booster dose
from the MVADC12L vectors generated an enhancement of the
specific cellular response, and moreover the breadth of the HIV-
responses was improved as positive T-cell responses against a
wider spectrum of peptides were detected for both recombinants.
For the NefBF antigen we have previously reported that after
DNA/MVA immunization a low immunogenicity was detected
against NefBF, which could be incremented if 36DNA sequential
immunizations were applied during priming [38]. A fact to be
denoted is that when the MVADC12L-NefBF was applied at
boosting after the DNA priming doses, a significant increment in
the response against Nef HIV was achieved, comparable to that
found when three DNA priming doses were applied. A possible
mechanism explaining why the absence of IL-18 bp viral activity
at the moment of the MVA boost can mediate an enhancement of
the DNA-primed HIV responses, may be the positive regulatory
loop involving IFN-c and IL-18 signaling recently proposed to be
contributing to the accelerated memory CD8
+ T-cell proliferation
during a recall response to antigens presented by DCs [50].
In summary, these results showed that the MVA 008L (C12L)
gene encodes for a protein with a clear biological activity that
inhibits the action of IL-18, and that the deletion from its genome
abolished this inhibitory activity. Analysis of the in vivo effects of
IL-18 bp after immunization with MVADC12L showed that at
early times post-inoculation higher numbers of T CD8
+ and CD4
+
anti-VACV IFN-c and IL-2 secreting cells were generated.
Importantly, we found that MVADC12L administration also
improved the number of CD8
+ T-cells with cytotoxic properties.
At later times post-immunization MVA inoculated mice still
maintained higher CD8
+ and CD4
+ T-cell VACV-specific
responses, which were correlated with an increased protection
against an i.n WR challenge. Finally, in DNA prime/MVA boost
regimes, the delivery of HIV antigens during the booster dose from
a MVADC12L vector generated an enhancement of the T-cell
response against the HIV proteins, improving the breadth, as
significant responses against a wider spectrum of antigens were
detected. These results are of high relevance for the design of new
optimized poxvirus vector based vaccines.
Materials and Methods
1. Cells
Primary cultures of chicken embryo fibroblasts (CEFs) were
prepared by the Tissue Culture Section of the INTA-Castelar
Virology Institute, from 11 days old specific pathogen free (SPF)
embryos (Instituto Rosenbusch, Argentina) and maintained in 199
Earle Medium supplemented with 2.95 mg/mL tryptose phosphate
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Biomedicals Inc., Irvine, CA), 0.3 mg/mL L-glutamine, 50 mg/mL
gentamicin, 66 mg/mL streptomycin, 100 U/mL penicillin and
10% fetal bovine serum (FBS, Internegocios, Argentina).
Stable cell lines employed in the study were: BSC-40 (epithelial
adherent cell-line derived from African green monkey kidney cells,
ATCC Cat. Nu CRL-2761); BHK-21 (fibroblast adherent cell-line
derived from hamster Syrian golden kidney cells, ATCC Cat Nu
CCL-10) and P815 (DBA-2 mice mastocytoma cells, ATCC Cat
Nu TIB-64); DF-1 cells (a spontaneously immortalized chicken
embryo fibroblast cell line, ATCC, Manassas, VA).
Cells were maintained at 37uC in a 5% CO2 atmosphere in
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented
with 10% FBS (DMEM 10% FBS).
2. Construction of plasmid transfer vectors
In order to obtain the different MVADC12L vectors employed
in this study two transfer plasmid vectors were generated. For the
construction of the pDC12L plasmid transfer the flanking regions
of 008L gene (coding for IL-18 bp, nt 13052–13414) were
amplified by PCR and cloned sequentially into pBlueScript
(Stratagene). The left and right flanks were 330 and 374 bp
length encompassing MVA genomic positions 12730–13059 and
13416–13789, respectively. The pairs of primers used were 008i1
GAATTCGTTGTTTACTCAAAACG/008i2 GGATCCGAA-
GTAGTGCGTGCTAC and 008d1 GCGGCCGCCTTGCCA-
AAATATCAC/008d2 GAGCTCCTATAATGATTATATAG,
for left and right flanks respectively. Recognition sites for
restriction enzymes used for cloning are showed underlined. The
intermediate plasmid obtained was named pBS-008. Then, the lac
Z gene (coding the b-galactosidase enzyme [bGAL]) under
regulation of poxviral H6 promoter was excised from a plasmid
available in our laboratory and it was subcloned into pBS-008 to
obtain pDC12L transference vector. The identity of all plasmids
was verified by DNA sequencing using an ABI PRISH 310 Genetic
Analyzer (Applied Biosystems, Japan).
The plasmid transfer vector pGem-RG-C12L, used for the
construction of recombinant virus MVADC12L-C in which C12L
ORF has been replaced for a GFP expression cassette, was obtained
bythesequential cloning offourDNAfragmentscontainingdsRed2
and rsGFP genes and C12L recombination flanking sequences into
the plasmid pGem-7Zf(2) (Promega). The dsRed2 gene under the
control of the synthetic early/late promoter (783 bp) was obtained
by digestion of plasmid pG-dsRed2 (encoding dsRed2 and rsGFP
genes) with Xba I and Eco RI and inserted into the Xba I/Eco RI-
digested pGem-7Zf(2) to generate pGem-Red. The rsGFP gene
under the controlof the synthetic early/late promoter was amplified
by PCRfrom plasmid pG-dsRed2 with oligonucleotides GFP-C (59-
GTTGGATCGATGAGAAAAATTG-39) (Cla I site underlined)
and GFP-B (59-CTATAGGATCCTCAAGCTATGC-39) (Bam HI
site underlined) (828 bp), digested with Cla I and Bam HI and
inserted into plasmid pGem-Red previously digested with Cla I and
Bam HI to obtain pGem-Red-GFP. MVA genome was used as the
template to amplify the left flank of C12L gene (375 bp) with
oligonucleotides fiC12L-BF (59-AGGATGGATCCCTTGCCAA-
AATAT-39) (Bam HI site underlined) and fiC12L-BR (59-
TATATGGATCCTTGCAATTAAG-39) (Bam HI site under-
lined). This left flank was digested with Bam HI and cloned into
plasmid pGem-Red-GFP previously digested with the same
restriction enzyme to generate pGem-RG-fiC12L. The right flank
of C12L gene (404 bp) was amplified by PCR from MVA genome
with oligonucleotides fdC12L-S (59-CAAAACCCGGGATAAA-
TACGAGG-39) (Sma I site underlined) and fdC12L-C (59-
GGCTGATCGATTGCGTGCTAC-39) (Cla I site underlined),
digested with Sma I and Cla I and inserted into the Sma I/Cla I-
digested pGem-RG-fiC12L. The resulting plasmid pGem-RG-
C12L was confirmed by DNA sequence analysis and directs the
insertion of GFP gene into C12L locus of MVA-C.
3. Genetic modification of MVA
The deleted MVADC12L vector used in this work was
generated using the clonal isolate MVA-F6, obtained after 582
passages in CEF cells [1], kindly provided by G. Sutter (Germany).
Mutant MVAs were obtained following infection-transfection
method previously described [53], employing monolayers of
CEFs and the pDC12L transference vector described above.
MVADC12L was wt virus-free after six consecutive rounds
of plaque purification on CEF cells in the presence of bGAL
substrate (bluo-gal, halogenated indolyl-b-galactoside, Inalco,
Italy). Purity of the selected clones was verified by PCR.
MVADC12L-NefBF was generated using MVA-NefBF virus
[36] and pDC12L transference vector by infection/transfection
method as described above, after six rounds of plaque purification.
The MVADC12L-C vector was constructed by transient dominant
selection using dsRed2 gene as the transiently selectable marker.
MVADC12L-C was selected from progeny virus by consecutive
rounds of plaque purification in DF-1 cells during which plaques
were screened for Red2/GFP fluorescence. In the first three
passages viruses from selected plaques expressed both fluorescent
proteins while in the last three passages (six passages in total) viral
progeny from selected plaques expressed only GFP due to the loss
of dsRed2 marker.
4. In vitro characterization of MVADC12L viruses
The deletion of 008L gene was confirmed by PCR using specific
primers. Total DNA was extracted from uninfected or MVA and
MVADC12L infected CEFs as described before [51]. The
presence of 008L and 165R (coding for viral hemagglutinin) genes
were evidenced by the amplification of a 1060 or 948 bp
fragments using the following pairs of primers: 008i1/008d2 and
HA1/HA4 [54], respectively. In order to evaluate the transcrip-
tion of 008L gene a RT-PCR was performed. Briefly, BHK-21 cell
monolayers were uninfected or infected with MVA (wt o
MVADC12L) at moi of 1. Twenty-four hs post inoculation (hpi)
cells were harvested and RNA was extracted using TrizolH,
according to the manufacturer instructions (Invitrogen, CA, USA).
RNA samples were treated with DNase I (Invitrogen) and
conserved at 270uC until used. RNA was reverse-transcribed
with the reverse transcriptase M-MLVRT (200 U, Promega) using
random hexamers. The cDNA obtained was used to amplify by
PCR a fragment of 363 bp corresponding to the complete coding
sequence for IL-18 bp. Primers used were 008L-F 59AT-
GAAAATCCTATTTCTCATCGC and 008L-R 59 CTACTT-
CAGCCAAATATTCT. To analyze kinetics of virus growth,
CEFs monolayers grown in 60 mm tissue culture dishes were
infected at 0.01 pfu/cell with MVAwt or MVADC12L. After
45 min of virus adsorption, the inoculum was removed, cells were
washed twice and incubated with fresh medium plus 2% of FBS.
For each virus and time-point (0; 6; 12; 16; 20; 24; 36; 48 and 72 h
post-infection) cells (intracellular virus) and supernatants (extra-
cellular virus) were collected separately, frozen/thawed three times
and stored at 270uC until virus titers were determined by
visualization of lysis plaques on CEFs. Each time point was
evaluated by duplicate and each fraction was tittered twice.
5. Viral immunization stocks
Viral stocks were grown in BHK-21 cells (for MVA vectors) or
BSC-40 cells (for VACV WR strain), viruses were released from
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centrifugation through a sucrose cushion and titrated by
immunostaining [55] in BHK-21 cells using a rabbit polyclonal
antibody against VACV antigens (for MVA) or by plaque
formation in BSC-40 cells using crystal violet (for WR).
6. IL-18-induced production of IFN-c
Functional assays to evaluate the effects of C12L gene deletion
on the IFN-c production were performed as previously described
[18]. Briefly, cultures of CEF cells were infected with MVAwt or
MVADC12L at 5 pfu per cell. Supernatants from infected cells
were harvested one day post-infection (dpi), centrifuged at
3000 rpm for 10 min at 4uC and the pellet was discarded.
Residual viral particles were removed by centrifugation at
16.500 rpm for 60 min at 4uC and supernatants were stored at
220uC until use. Then, splenocytes from BALB/c naı ¨ve mice
were cultured in RPMI 1640 medium plus 10% FBS (RPMIc)
with 200 ng/ml concanavalin A (Con A) and 5 ng/ml murine IL-
18 for 24 hs at 37uC. To test for inhibition of IL-18 action by the
C12L protein, recombinant murine IL-18 was pre-incubated for
1 hr at room temperature with clarified supernatants from CEF
cells that had been infected with the viruses. Finally, levels of IFN-
c in the culture medium were determined by a standard ELISA
following the instruction of the manufacturer (BD Biosciences).
7. Immunization protocols, sample collection and
processing
SPF BALB/c (H-2d) and C57BL/6 (H-2b) female mice, six to
eight weeks old were purchased from the Laboratories of the
School of Veterinary Sciences, University of La Plata, Buenos
Aires, and then housed in our animal facilities. All experiments
were carried out in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health [45]. The protocol was approved by
the Committee of Care and Use of Laboratory Animals from the
School of Medicine, University of Buenos Aires (Permit Number:
508/2009). Immunizations with viral vectors were given intraper-
itoneally (i.p) in 200 ml of PBS, intramusculary (i.m) in 200 mlo f
PBS (100 ml in each leg), subcutaneously (s.c) in 200 mlo fP B S
(100 ml in each leg, near to the groin region), or intranasally (i.n) in
20 ml of PBS (10 ml in each nasal fose). For DNA prime/MVA
boost schemes, DNA doses were applied in 100 ml of sterile PBS by
i.m route and 14 days after MVA boost was administered i.m or
i.p. Doses and periods of time used in the different immunization
schemes are depicted in the different Figures. Seven or forty days
after the immunization, mice were sacrificed and after the
recovery of spleens and draining lymph nodes (DLNs) under
sterile conditions cells were isolated by standard procedures.
8. Analysis of specific T-cell immune responses
8.1. Peptides for the evaluation of specific T-cell responses
against vector epitopes. All VACV-specific synthetic peptides
used in this work(8 or 15 aa long) werepurchased from JPT Peptide
Technologies (Germany). Lyophilized peptides were dissolved in
dimethyl sulfoxide (DMSO) and stored at 220uC. All peptides were
used at a final concentration of 2 mg/ml. E3 and F2(G) peptides
have been previously described as CD8
+ specific epitopes in BALB/
c mice [56]; B8R (CD8
+) and E9L, H3L, L4R (CD4
+) are specific
epitopes previously defined in C57BL/6 mice [28]. P815 (H-2d
restricted) infected cells were used as APCs following the protocols
described previously [57].
8.2. Evaluation of specific T-cell responses against HIV-1
antigens. Overlapping synthetic peptides (13–15-mers, over-
lapping by 11 aa) were designed based on the Nef protein from
CRF12_BF reference strain ARMA185, the same sequence
employed for the construction of the DNA and MVA vectors
that expressed this protein, and custom ordered from JPT Peptide
Technologies (Germany). Overlapping synthetic peptides of NefB
consensus protein were obtained from the NIH AIDS Reagent
Program (catalog Nu 9480). The peptides employed to evaluate the
response against the HIV-1 subtype C antigens were previously
described [39], they spanned the entire Env, Gag, Pol and Nef
regions from clade C included in the immunogens as consecutive
15-mers overlapped by 11 amino acids. The CN54gp120 protein
(499 aa) was spanned by the Env-1 (aa: 1–239; 49 peptides) and
Env-2 (aa: 229–499; 63 peptides) pools. The Gag-Pol-Nef fusion
protein (1417 aa) was spanned by the following pools: Gag-1 (aa:
1–254; 60 peptides), Gag-2 (aa: 244–500; 61 peptides),GPN-1 (aa:
485–735; 60 peptides), GPN-2 (aa: 725–831 and aa: 1017–1175;
61 peptides), GPN-3 (aa: 1165–1417; 61 peptides) and Nef (aa:
838–1044;49 peptides). Lyophilized peptides were dissolved in
DMSO and stored at 220uC.
8.2.1 Murine IFN-c and IL-2 Elispot assays. Elispot assays
were performed using freshly isolated splenocytes and cells from
DLNs as previously described [24]. Briefly, 2610
5 to 10
6 cells in
RPMIc were plated in triplicate on nitrocellulose 96-well plates
(MultiScreen HA plates; Millipore Corporation, Bedford) pre-
viously coated with an anti-mouse IFN-c Ab (BD Pharmingen Rat
anti-mouse IFN-c, XMG1.2) oranti-mouse IL-2Ab (BD ELISPOT
Mouse IL-2 ELISPOT Pair). Stimulus consisted of VACV-specific
individual peptides or overlapping synthetic peptides covering
NefBF, NefB and different HIV-1 subtype C antigens as described
above. To evaluate responses against P815-MVA infected cells,
previously described protocols to infect the P815 H-2d MHC class I
restricted cells, were followed [58]. Negative controls were
incubated with RPMIc with the appropriate % of DMSO, and
cells treated with ConA (1 mg/ml) were includedas positivecontrol.
The threshold values to consider a positive response by Elispot
was that the number of specific spots/well had to be at least 2
times the average values found in negative control wells of each
group. For evaluation of the response in the memory phase, the
IFN-c Elispot assay was performed using more sensitive anti-
mouse IFN-c Abs (BD ELISPOT Mouse IFN-c ELISPOT Pair)
which allowed the detection of subtle differences between vectors
given the expected general reduction on the magnitude of the
response at later times post-infection.
Functional avidity referred to as the activation threshold in
response to defined concentrations of exogenous peptide was
performed following the protocols previously described [59].
Briefly, limiting peptide dilutions (from 20 to 2610
26 mg/ml)
were performed and then the peptide concentrations needed to
produce half-maximum IFN-c production (number of spots) were
calculated in ex vivo assays. Values of peptide concentrations
needed for 50% of the maximal T-cell responses (EC50) were
calculated with sigmoidal dose-response curves obtained with the
GraphPad software.
8.2.2 Simultaneous intracellular cytokine staining (ICS)
and cytotoxic activity assessment. Splenocytes were
dispensed in 96-well U bottom plates (2610
6 cells/well) and
were stimulated with the VACV-specific peptides during 5 hs at
37uCi n5 %C O 2 in the presence of the costimulatory antibody
anti-CD28 (1 ng/ml; BD Biosciences), brefeldin A (1 ml/ml
GolgiPlug; BD Biosciences), monensin (0.7 ml/ml GolgiStop; BD
Biosciences) and the monoclonal Abs (mAb) anti-CD107a and
anti-CD107b both labeled with FitC (CD107a/b-FitC; BD
biosciences; this molecules are degranulation markers, and
allowed the detection of cytotoxic activity of CD8
+ cells [60]).
Negative and positive controls consisted of cells stimulated with
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phorbol myristate acetate [PMA] plus 250 ng/ml ionomycin
[Sigma-Aldrich]) respectively). Afterwards, cells were washed and
stained with surface antibodies (CD3-APC and CD8-PerCP; BD
Biosciences) for 30 min at 4uC, and then permeabilized and fixed
using the Cytofix/Cytoperm kit (BD Biosciences). After the
permeabilization/fixation step, cells were stained using anti-
tumor necrosis factor alpha (TNF-a) antibody labeled with PE-
Cy7 (TNF-a-PE-Cy7; BD Biosciences) and anti-IFN-c labeled
with phycoerythrin (IFN-c-PE; BD Biosciences) for 30 min at 4uC
in obscurity, after two washes cells were stored at 4uC until being
acquired in a BD FACSCanto flow cytometer. Data acquisition
and analysis were done with the BD FACSDiva software.
Instrument settings and fluorescence compensation were
performed on each testing day using unstained and single-
stained samples. Stimulated cells stained for surface molecules
and isotype matched controls were included in each experiment.
8.2.3 T-cell specific cytokine production. Splenocytes
were suspended in RPMIc and cultured in triplicate (10
6 cells/
well) into 96-well microtiter flat-bottom plates and stimulated with
the indicated peptides. Positive and negative controls were cells
stimulated with Con A (1 mg/ml), and with medium plus the
appropriate % of DMSO respectively. After 72 hr incubation at
37uCi n5 %C O 2, culture supernatants were harvested at 280uC
and analyzed by ELISA for IFN-c (BD OptEIA Set Mouse IFN-c)
and TNF-a (BD OptEIA Set Mouse TNF mono/poly) following
the manufacturer’s instructions.
9. Intranasal challenge with replication competent WR
Groups of eleven BALB/c mice were vaccinated with 10
6 pfu of
MVAwt, MVADC12L or mock inoculated by the i.p route. At 45
days post-immunization, animals were anesthetized by i.p
injection of ketamine (0,1 mg/g) and xylazine (0,01 mg/g),
infected i.n with Vaccinia virus WR (2610
6 pfu diluted in 20 ml
PBS, 10 ml in each nasal fose) and monitored for at least 12 days
for morbidity and mortality, with daily measurement of individual
body weights and observation of signs of illness as described
previously [52]. In brief, signs of illness recorded were: bristly fur
curved back, difficulty to breathe, reduced motility, and corporal
tremors; they were measured by the assignment of a score
proportional to the number of signs present in each mouse.
Animals suffering from severe systemic infection and having lost
.30% body weight were sacrificed (humane end point). The % of
accumulative body weight loss was calculated as the relative %
weight loss registered each day with respect to the immediate
previous day plus the % weight loss accumulative registered until
that moment. Thus, the % of accumulative weight (W) loss
registered at n day was calculated with the following formula:
X n
1
W(n{1){Wn
    
Wn)|100
10. Data analysis
All data were expressed as the mean 6 SD of triplicate (Elispot)
and duplicate (ELISA and ICS) determinations for each group,
and are representative of at least three independent experiments.
The significance of differences between the different groups of
immunized mice was determined using the two-tailed Student’s t
test or the Mann Withney test (GraphPad Prism4 software). Values
of p#0.05 were considered statistically significant.
Supporting Information
Figure S1 Mice vaccinated with MVADC12L show less
signs of illness after a VACV challenge. The three groups of
BALB/c mice used in the VACV challenge (see legend Fig. 6C)
were also monitored for signs of illness appearance as described in
Materials and Methods. The figure shows the mean score 6 SD
for each group from days 5 to 8 at which differences in weight loss
were substantial (see Fig. 6C and D). The asterisks represent the
statistically significant differences between MVAwt vs.
MVADC12L (** p,0.01, *** p,0.001). Statistically significant
differences between mock-vaccinated vs. both MVAwt and
MVADC12L groups: w p,0.001.
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